{
    "data": [
        {
            "id": "4561064",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-29T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1397180904/image_1397180904.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Share Price Growth In 2022 Best For A Decade - But 2023 Could Better It",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "422955",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4561064-bristol-myers-squibb-stock-price-growth-2023-could-better-2022"
            }
        },
        {
            "id": "4560662",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-27T01:57:01-05:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is Still An Attractive Addition To Your Dividend Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "422516",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4560662-bristol-myers-squibb-still-attractive-addition-to-dividend-growth-portfolio"
            }
        },
        {
            "id": "4550256",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-28T08:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1341512128/image_1341512128.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb And Gilead - Still A Buy After Strong Q3?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "417037",
                            "type": "sentiment"
                        },
                        {
                            "id": "417038",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4550256-bristol-myers-squibb-gilead-strong-q3-earnings"
            }
        },
        {
            "id": "4549089",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-26T10:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/158759380/image_158759380.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Looking Down A Patent Cliff",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106588",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "416361",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4549089-bristol-myers-squibb-looking-down-a-patent-cliff"
            }
        },
        {
            "id": "4544208",
            "type": "article",
            "attributes": {
                "publishOn": "2022-10-02T01:58:20-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1327624070/image_1327624070.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: A Gem In A Period Of Macroeconomic Uncertainties",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "412033",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4544208-bristol-myers-squibb-a-gem-in-a-period-of-macroeconomic-uncertainties"
            }
        },
        {
            "id": "4542798",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-23T16:56:14-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1049293884/image_1049293884.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Sotyktu Approval Sends Ventyx Stock Soaring: Consider Buying Both",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "410755",
                            "type": "sentiment"
                        },
                        {
                            "id": "410756",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4542798-bristol-myers-sotyktu-approval-sends-ventyx-stock-soaring"
            }
        },
        {
            "id": "4540213",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-11T06:12:47-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1327624070/image_1327624070.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Still A Buy Despite Some Concerns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106413",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "408346",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4540213-bristol-myers-squibb-stock-still-a-buy-despite-some-concerns"
            }
        },
        {
            "id": "4540078",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-09T17:18:17-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1418324628/image_1418324628.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stronger Outlook For Bristol-Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20102",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "408429",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4540078-stronger-outlook-for-bristol-myers-squibb"
            }
        },
        {
            "id": "4533710",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-12T16:49:36-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1208332812/image_1208332812.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Keep Buying On Good (But Not Great) Performance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "387481",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4533710-bristol-myers-squibb-stock-keep-buying-good-not-great-performance"
            }
        },
        {
            "id": "4531862",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-09T05:45:19-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1330681654/image_1330681654.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Earning 10% Income On Bristol Myers Squibb With Options",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106490",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "386742",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4531862-bristol-myers-squibb-earning-10-percent-income-options"
            }
        },
        {
            "id": "4528381",
            "type": "article",
            "attributes": {
                "publishOn": "2022-08-01T18:47:03-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320311776/image_1320311776.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Nowhere To Go Even After Q2",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106667",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385421",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4528381-bristol-myers-squibb-nowhere-to-go-even-after-q2"
            }
        },
        {
            "id": "4527418",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-29T10:30:05-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304173435/image_1304173435.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Q2 Earnings Performance Confirms My Bullish Stance",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385128",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4527418-bristol-myers-squibb-q2-earnings-performance-bullish"
            }
        },
        {
            "id": "4527320",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-29T03:17:46-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364982274/image_1364982274.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Growth Plans And Q2 2022 Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "385068",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4527320-bristol-myers-squibb-stock-growth-plans-q2-2022-earnings"
            }
        },
        {
            "id": "4525219",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-23T07:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Stocks To Watch: Apple, Amazon, Microsoft And Meta Platforms Headline Huge Week Of Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4525219-stocks-to-watch-apple-amazon-microsoft-and-meta-platforms-headline-huge-week-of-earnings"
            }
        },
        {
            "id": "4520933",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-29T10:20:58-04:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1352510237/image_1352510237.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: When Will The Correction End?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106297",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380538",
                            "type": "sentiment"
                        },
                        {
                            "id": "380539",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4520933-bristol-myers-squibb-when-will-the-correction-end"
            }
        },
        {
            "id": "4520896",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-29T05:45:02-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Stock: Downgrade To Hold Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380378",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4520896-bristol-myers-squibb-downgrade-hold"
            }
        },
        {
            "id": "4520833",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-28T18:56:28-04:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Look For The Exit",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380405",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4520833-bristol-myers-squibb-look-for-the-exit"
            }
        },
        {
            "id": "4520830",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-28T18:46:52-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1383260152/image_1383260152.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Is Melting-Up Again",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380396",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4520830-bristol-myers-is-melting-up-again"
            }
        },
        {
            "id": "4520739",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-28T12:17:59-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1302272258/image_1302272258.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Annual Mid Single-Digit Growth Equals Incremental Upside",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "380370",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4520739-bristol-myers-squibb-annual-mid-single-digit-growth-incremental-upside"
            }
        },
        {
            "id": "4516721",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-06T15:59:40-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325872227/image_1325872227.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Merger Arbitrage Mondays: Bristol Myers Acquires Turning Point Therapeutics",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "377168",
                            "type": "sentiment"
                        },
                        {
                            "id": "377169",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4516721-merger-arbitrage-mondays-bristol-myers-acquires-third-point-therapeutics"
            }
        },
        {
            "id": "4515104",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-28T03:35:00-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325076942/image_1325076942.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: A Safe Spot For A Worrisome Investor",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106380",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "375923",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4515104-bristol-myers-squibb-safe-spot-worrisome-investor"
            }
        },
        {
            "id": "4514441",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-25T13:37:02-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/673436632/image_673436632.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb Vs. AbbVie: Who Better Fits Our Barbell?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "375601",
                            "type": "sentiment"
                        },
                        {
                            "id": "375602",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4514441-bristol-myers-squibb-abbvie-who-fits-barbell"
            }
        },
        {
            "id": "4513533",
            "type": "article",
            "attributes": {
                "publishOn": "2022-05-20T18:06:03-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316775813/image_1316775813.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: A Safe Haven In Times Of Uncertainty",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105586",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "374867",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4513533-bristol-myers-squibb-safe-haven-times-of-uncertainty"
            }
        },
        {
            "id": "4503237",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-25T00:14:10-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/545377376/image_545377376.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Fading The Rally Before Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "371007",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4503237-bristol-myers-squibb-fading-rally-before-earnings"
            }
        },
        {
            "id": "4502288",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-20T09:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1320838258/image_1320838258.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb - AbbVie 2.0?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "370359",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4502288-bristol-myers-squibb-abbvie-2-0"
            }
        },
        {
            "id": "4496603",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-19T08:40:33-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322800279/image_1322800279.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Still On Track",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106331",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366156",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496603-bristol-myers-squibb-on-track"
            }
        },
        {
            "id": "4495973",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-16T15:50:54-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/467466545/image_467466545.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Consistently Hitting Targets, New Drug Launches Drive Share Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "365845",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4495973-bristol-myers-squibb-hitting-targets-new-drug-launches"
            }
        },
        {
            "id": "4488025",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-17T14:52:23-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb Is My Choice For A Dividend Growth Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80836",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "362039",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4488025-bristol-myers-squibb-for-dividend-growth"
            }
        },
        {
            "id": "4487804",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-17T06:55:31-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/image_1077050386.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb: Bull Thesis Supported By Both Strong Technical And Fundamental Signals",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106207",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "361965",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4487804-bristol-myers-squibb-bull-thesis-supported-strong-technical-fundamental-signals"
            }
        },
        {
            "id": "4484725",
            "type": "article",
            "attributes": {
                "publishOn": "2022-02-06T08:29:32-05:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1297582177/image_1297582177.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Strong Q4 Results Strengthen The Bull Case",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106413",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "360270",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4484725-bristol-myers-squibb-strong-q4-earnings-bull-case"
            }
        },
        {
            "id": "4480018",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-17T15:41:23-05:00",
                "isLockedPro": false,
                "commentCount": 27,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1287257611/image_1287257611.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb Looks Strong In 2022, Century Deal Can Help Establish Cell Therapy Leadership",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "357492",
                            "type": "sentiment"
                        },
                        {
                            "id": "357493",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4480018-bristol-myers-squibb-looks-strong-in-2022-century-deal-can-help-establish-cell-therapy-leadership"
            }
        },
        {
            "id": "4479027",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-11T12:33:01-05:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277229026/image_1277229026.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol Myers Squibb Shares Are Still Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "356592",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4479027-bristol-myers-squibb-shares-are-still-undervalued"
            }
        }
    ]
}